Literature DB >> 28346419

Evolving concepts in prognostic scoring of chronic GvHD.

A Lazaryan1, M Arora1.   

Abstract

Chronic GvHD (cGvHD) remains one of the most complex and challenging complications after allogeneic hematopoietic cell transplantation. Emerging knowledge about the clinical manifestations and associated organ involvement of cGvHD has led to the establishment of prognostic parameters for post-transplant survival among affected allograft recipients. Studies employing the pre-National Institutes of Health (NIH) consensus data on cGvHD incidence and its risks have led to development of the CIBMTR's cGvHD risk stratification, which serves as the most refined and validated prognostic tool for estimating survival of patients with cGvHD. However, cGvHD global severity scoring has recently evolved as a powerful prognostic tool for patient survival in the post-NIH consensus era. Current use of the substantially redefined NIH criteria of cGvHD diagnosis and measurements of its severity makes it challenging to interpret prognostic scoring systems generated in the pre-NIH era. Some of the pre-NIH prognostic parameters, however, appear to retain their significance in predicting survival independently from the NIH global severity score. Thus, future analyses of prospective cohorts of patients with cGvHD defined by NIH consensus criteria will be critical in reconciling and integrating various prognostic scoring systems of cGvHD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28346419     DOI: 10.1038/bmt.2017.50

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  47 in total

1.  Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.

Authors:  David A Jacobsohn; Brenda F Kurland; Joseph Pidala; Yoshihiro Inamoto; Xiaoyu Chai; Jeanne M Palmer; Sally Arai; Mukta Arora; Madan Jagasia; Corey Cutler; Daniel Weisdorf; Paul J Martin; Steven Z Pavletic; Georgia Vogelsang; Stephanie J Lee; Mary E D Flowers
Journal:  Blood       Date:  2012-07-06       Impact factor: 22.113

2.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

3.  Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study.

Authors:  Joseph Pidala; Georgia Vogelsang; Paul Martin; Xiaoyu Chai; Barry Storer; Steven Pavletic; Daniel J Weisdorf; Madan Jagasia; Corey Cutler; Jeanne Palmer; David Jacobsohn; Sally Arai; Stephanie J Lee
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

4.  Clinical benefit of response in chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Paul J Martin; Xiaoyu Chai; Madan Jagasia; Jeanne Palmer; Joseph Pidala; Corey Cutler; Steven Z Pavletic; Mukta Arora; David Jacobsohn; Paul A Carpenter; Mary E D Flowers; Nandita Khera; Georgia B Vogelsang; Daniel Weisdorf; Barry E Storer; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-06       Impact factor: 5.742

5.  The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series.

Authors:  Cristina Tecchio; Federico Mosna; Angelo Andreini; Laura Paoli; Raimondo Di Bella; Donata de Sabata; Marco Sorio; Giovanni Pizzolo; Fabio Benedetti
Journal:  Leuk Lymphoma       Date:  2013-02-19

6.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

7.  Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation.

Authors:  Simonetta Spinelli; Sandra Chiodi; Sergio Costantini; Maria Teresa Van Lint; Anna Maria Raiola; Gian Battista Ravera; Andrea Bacigalupo
Journal:  Haematologica       Date:  2003-10       Impact factor: 9.941

8.  Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.

Authors:  Madan Jagasia; Jennifer Giglia; Wichai Chinratanalab; Sheri Dixon; Heidi Chen; Haydar Frangoul; Brian Engelhardt; Stacey Goodman; John Greer; Adetola Kassim; David Morgan; Katherine Ruffner; Friedrich Schuening
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-24       Impact factor: 5.742

9.  Feasibility of NIH consensus criteria for chronic graft-versus-host disease.

Authors:  B-S Cho; C-K Min; K-S Eom; Y-J Kim; H-J Kim; S Lee; S-G Cho; D-W Kim; J-W Lee; W-S Min; C-C Kim
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

10.  Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes.

Authors:  L R First; B R Smith; J Lipton; D G Nathan; R Parkman; J M Rappeport
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

View more
  3 in total

Review 1.  How I treat refractory chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Adela R Cardones; Keith M Sullivan
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

2.  Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.

Authors:  Vijaya Raj Bhatt; Tao Wang; Karen Chen; Carrie L Kitko; Margaret L MacMillan; Joseph A Pidala; Monzr M Al Malki; Sherif M Badawy; Amer Beitinjaneh; Siddhartha Ganguly; Betty Hamilton; Gerhard C Hildebrandt; Lazaros J Lekakis; Hongtao Liu; Richard T Maziarz; Dipenkumar Modi; Hemant S Murthy; Jaime M Preussler; Akshay Sharma; Stephen R Spellman; Mukta Arora; Stephanie J Lee
Journal:  Transplant Cell Ther       Date:  2021-10-09

3.  Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.

Authors:  Ana Zelic Kerep; Jacob Broome; Filip Pirsl; Lauren M Curtis; Seth M Steinberg; Sandra A Mitchell; Edward W Cowen; Dominique C Pichard; Galen O Joe; Leora E Comis; Jacqueline W Mays; Manuel B Datiles; Pamela Stratton; Jessica Zolton; Ann Berger; Jennifer Hendricks; Megan Kenyon; Judy Baruffaldi; Irina Titarenko; Drazen Pulanic; Kristin Baird; Daniel H Fowler; Ronald E Gress; Steven Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2018-08-08       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.